

CUKIERMAN & CO.
Life Sciences

&

GoforIsrael

invite you to the

COVID-19 INNOVATION CONFERENCE

APRIL 6-7, 2020

COMPANIES FIGHTING COVID-19

Online Worldwide Investment Event

For Life Sciences Start-ups Fighting the Pandemic



Global



Funding



Partnerships



1:1 Meetings

- www.cukiermanlifesciences.com
- www.goforisrael.com

	<p>Respinova Ltd.</p>	<p>Cliff Ansel</p>	<p>Respinova Ltd. is an Israeli company developing Pulsehaler, a novel therapy for treating COVID-19 and chronic lung disease (COPD). In both diseases, lung airways close and can fill with sticky mucus, preventing oxygen from entering the body. Pulsehaler has been clinically proven to re-open these closed and blocked airways.</p>
	<p>Genoscience Phama</p>	<p>Philippe Halfon</p>	<p>Genoscience Pharma, a French clinical-stage biotechnology company, is developing a potential new disruptive standard of care against liver cancers thanks to its platform.</p>
	<p>Preci Health</p>	<p>Lucien Vouillamoz</p>	<p>PreciHealth SA (PH) a Swiss-based MedTech company offering a true first-in-class breakthrough for the rapidly expanding pre-filled auto-injectors and blood sampling market. For auto-injectors PH is the first company in decades to revolutionize the injection process both for intra-muscular and subcutaneous auto-injections. Small, easy to use, safe and cost effective PH self-injectors can be used for mass vaccination during pandemics to come. For blood sampling during pandemics, monitoring the level of immunization of exposed populations is paramount to controlling the spread of the pandemic. PH is developing its patent pending self-blood-sampler. Finally, combination self-injectors + self-blood-samplers can be used for patients under strict isolation who are often required to treat themselves under remote directions from the medical staff. The company is expanding its current strategy towards these indications, helping to fight the COVID-19 and pandemic to come.</p>



Enlivex
Therapeutics

Shai Novik

Clinical-stage therapy for organ failure of COVID-19 patients in the ICU. Currently in clinical studies for sepsis, which is a dominant cause of mortality for COVID-19 patients in the ICU.



Sonovia

Roy Hirsch
& Rom
Eliaz

Our Company - Sonovia Ltd., is an Israeli start-up company developing life-saving technologies, originally adapted from the prestigious Bar Ilan University in Israel. At its core, the technology provides a novel, ultrasound-based, high-efficacy zinc-oxide textile coating, which kills microbes at the surface of the textile. Our sono-coating process ensures the zinc oxide is durably impregnated into the fabric, making the fabrics washable and reusable.

In light of the recent COVID-19 pandemic, the advancement of protective technologies and public health solutions has never been more imperative. Given Sonovia's one-of-a-kind, durable, anti-microbial coating; Sonovia Ltd is determined to use its novel technology for the good of the public welfare:

Sonovia has already proven high-efficacy [log5-log7] against a large variety of bacteria, and there is much academic literature [1-2]¹ indicating the efficacy of zinc-oxide ["ZnO"] against a variety of virus strains including Coronaviridae.

We are collaborating with several different labs internationally to attain the anti-viral active status of our treated textile. Despite the under-staffed laboratories and the difficulty of working with viral samples such as COVID-19, we will have the result soon. In the meantime please see below studies that demonstrate that the same metallic nanoparticles impregnated into our fabrics were innately anti-viral in several in-vitro studies. Therefore, it is highly probable that these fixed metallic nanoparticles will behave in the same way by the biochemical formation of reactive oxygen species which denature the lipid bilayer of micro-organisms including enveloped viruses such as COVID-19.



SoniVie Ltd

Charles S Carignan, MD, CEO

We have a therapeutic ultrasound treatment that may help treat underlying COPD in patients at risk for severe COVID-19 infection



Nanosono

Ronen Sarusi

Company description (related to COVID-19): NanoSono produce antibacterial raw material. Our material being tested in an FDA approved Lab for efficacy against COVID-19.



ContinUse Biometrics

Asher Polani

Using patented, clinically validated technologies, CU-BX's contact-free, remote patient screening and health monitoring solutions detect key physiological parameters and acoustics to enable safer and more efficient care practices such as the early detection of parameters and biomarkers associated with different cardiac and respiratory conditions, (e.g. COVID-19). Measured parameters include heart rate, respiratory rhythm, estimated blood pressure, cardiac acoustics and more. Measurement data is streamed to a GDPR-HIPAA compliant health cloud where machine learning models and AI techniques identify trends, alerts anomalies and biomarkers providing information to support actionable insights that enable better health, safety and wellbeing.

CU-BX technology maintains accuracy within multiple unique environments & conditions, working as a standalone device or when embedded into partner technologies. The system works in all lighting conditions, through multiple types of clothing and translucent materials (e.g. glass), and is unaffected by skin color or perspiration. Potential environments might include hospitals & clinics, homes, boarder control, travel platforms, offices, factories and other places of business, military bases and more.

	Serenno Medical	Tomer Lark	<p>Serenno is using a robust, hands-free, low cost and non-invasive device, monitoring ongoing kidney function (currently collected and calculated manually). Allowing contact free monitoring for hospitalized patients as well as quarantined and home ICU patients. Using the system medical personnel would reduce their exposure and only be alerted to conditions requiring immediate attention, able to predict and avoid kidney risks with no need for massive interventions. And so significantly reducing risk, LOS and costs.</p>
	Aero41 Ltd., part of Delta Drone Group	Frederic Hammeler	High precision AI-driven disinfection flying robot
	MagBiosense	Dr. Amos Danielli	MagBiosense develops highly sensitive and high throughput diagnostics devices for rapid detection of viruses, such as the SARS-Cov-2
	Seamless Vision	Amir Nardimon	<p>Short summary on your company : Seamless Vision have been working for the past 3 years on developing an autonomous robot which can guide low vision and blind people through urban areas. We have a working prototype which can lead a user in both indoor and outdoor scenarios and are now engaging with internal users to test the usability of the system alongside advancing our software features.</p> <p>In light of the Covid-10 pandemic we thought about how to help the fight against it. We came up with a concept of using our autonomous mobility platform and attaching a UV structure to it and using it to disinfect urban areas (i.e. hospitals, supermarkets, hotels, trains, transportation stations, malls, etc.).</p> <p>The device will be able to plan smart and highly efficient disinfection routes in those areas and with that save time and energy enabling us to dynamically disinfect more spaces in less time.</p>

	OTR3	Pr. Denis Barritault	Repurposing of an existing skin healing CE marked product for the protection, repair and functional recovery of lungs during and after COVID-19 induced SARS.
	ResMetrix Medical	Carmit Levy	<p>Resmetrix has developed a novel wearable respiratory monitoring system, that accurately monitors the respiratory pattern of respiratory disease patients (COVID-19, COPD, Asthma) and alert to the patient smartphone, and the medical team, when early signs of respiratory deterioration occur. Resmetrix unique wearable sensor (based on novel proprietary sensor built into a chest strap or a patch over the chest), wirelessly connected to a smartphone app, that monitors at-risk patients in real-time, 24/7, anywhere, in any setting. Resmetrix system is the only system that detects small changes in a patient's breathing pattern, tidal volume and other vital signs (Heart Rate, Temperature) and will provide immediate, early warning signs of deterioration in lung function (based on each patient respiratory pattern).</p> <p>Our telemonitoring system can monitor Corona patients at home, at isolation place or at the Hospital, send alarm to the medical teams when patients are deteriorating, so they can provide treatment early, hence avoiding lung failure and death.</p>
	Medlea	Simone Mlechianna	<p>MedLea S.r.l.s. is a start-up born in Rome, Italy in 2019. The founders hold a long experience and track record in bioengineering, physics, software development and academia (CNR, Harvard, EPFL, Cambridge, Rome Universities, authoring hundreds of scientific articles in leading international journals) leading to the development of an organic and highly configurable technology platform. MedLea is a software company that develops a breakthrough platform for general-purpose and custom respiratory diagnostics. Its technology covers the treatment and segmentation of medical images, the simulation of respiratory biomechanics, together with artificial intelligence at the service of patient-specific functional diagnosis.</p> <p>MedLea operates as an agile management team that targets recurring revenue streams via licenses, pay-per-click diagnostics and as technology providers. With existing IP, development and engineering capabilities all in place, MedLea establishes partnerships and license agreements in key sectors related to digital diagnostics.</p>



Cansino

CanSino is an innovative biopharmaceutical company dedicated to exploring best solutions to the prevention of diseases. Its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) candidate ("Ad5-nCoV"), co-developed with Beijing Institute of Biotechnology (BIB), has been approved to enter into Phase 1 Clinical Trial. It is currently the first novel coronavirus vaccine for COVID-19 that made to this stage in China.



Vocalis
Health

Tom
Wenderow